EGFR and neoplasm: These alterations are considered to be driven by changing circulating cytokines and chemokines profiles released by malignant cells such as TNFα, EGFR ligands, transforming growth factor‐beta (TGF‐β) and IL-6, contributing to local immune evasion and tumor progression [34].